南京5个平台入围，加速科技成果转化

Core Viewpoint - The Ministry of Industry and Information Technology has announced the preliminary list of key pilot platforms for technology transfer, with five platforms from Nanjing making the list, representing about one-fourth of the total 21 platforms in the province [1]. Group 1: Key Pilot Platforms - The five pilot platforms from Nanjing include: 1. Nanjing Fiberglass Institute Advanced Inorganic Fiber and Composite Materials Pilot Platform 2. Kingsray Life Sciences Formulation Pilot Platform 3. Pengbo Bio One-stop Biopharmaceutical Pilot Platform 4. Haina Pharmaceutical High-end Chemical Formulation Pilot Platform 5. China Unicom IoT Terminal Pilot Platform [1]. Group 2: Nanjing Fiberglass Institute - The Nanjing Fiberglass Institute focuses on high-performance fibers and their composite materials, providing specialized services for technology research and development, process improvement, and scaling up production [1]. - The platform aims to establish an open innovation platform with capabilities in digital design, advanced manufacturing technology research, and application service [1]. Group 3: Kingsray Life Sciences - The Kingsray Life Sciences platform utilizes artificial intelligence for online customization and design of life science reagents, enhancing research efficiency for biotechnology companies and pharmaceutical enterprises [2]. - It offers tailored products and services, including customized life science reagents and standardized experimental instruments [2]. Group 4: Pengbo Bio - The Pengbo Bio platform provides end-to-end CDMO services for antibody protein drugs, gene and cell therapy drugs, and vaccines, with a total production capacity of 2800L and an annual output of 104 batches [2]. - The Bio-MFG center has passed EU QP audits and holds a drug production license from Jiangsu Province, enabling it to offer preclinical non-GMP toxicology batch production and clinical GMP raw material production services [2]. Group 5: Haina Pharmaceutical - Haina Pharmaceutical has a highly qualified R&D team and advanced precision testing equipment, with over 11,000 square meters of laboratory space and 330 researchers [3]. - The platform covers all aspects of drug development, including pharmaceutical research, process validation, clinical research, biological testing, registration, and contract manufacturing [3]. Group 6: China Unicom IoT - The China Unicom IoT Terminal platform focuses on the "5G + Industrial Internet" transformation, establishing a pilot verification platform for IoT smart terminal production processes [3]. - It has received national CNAS laboratory certification and has served over 50 ecological partners, assisting in the development of more than 100 IoT smart terminal products [3]. Group 7: Future Plans - The Industrial and Information Technology Bureau plans to enhance tracking services for key pilot platforms, aiming to improve technology maturation, pilot verification, and achievement promotion capabilities [3]. - The goal is to fully leverage the role of pilot platforms to facilitate the final stage of technology transfer [3].